Patients with steroid-refractory aGVHD can be identified as early as 3 days from the start of treatment1
EBMT-NIH-CIBMTR Task Force Guidance Defines an Inadequate Response to Steroids1



Steroid-refractory acute GVHD is not uncommon. We know that approximately 50 percent of patients will require additional therapy.
Michael R. Bishop, MD
GVHD Expert

aGVHD=acute graft-versus-host disease; CIBMTR=Center for International Blood and Marrow Transplant Research; EBMT=European Society for Blood and Marrow Transplantation; NIH=National Institutes of Health; REACH=Ruxolitinib in patiEnts with refrACtory graft-versus-Host disease after allogeneic stem cell transplantation; SR=steroid refractory.
Reference: 1. Schoemans HM, Lee SJ, Ferrara JL, et al; for the EBMT Transplant Complications Working Party and the EBMT−NIH−CIBMTR GvHD Task Force. EBMT–NIH–CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant. 2018;53(11):1401-1415.